TET2 and Stroke: Given these findings, we chose to perform stroke surgeries between 8 and 10 w post-BMT, where we reasoned that the percentage Tet2-KO donor cells in the blood would be sufficient to potentially reveal any biological effect in stroke, in the absence of hematological differences between the two groups.